AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Lycia Therapeutics announced it raised $75 Million in an initial filing from an offering of $75 Million
PRIVATEJun 25, 2026•3 months ago
Amount Raised
$75 Million
Round Type
Series D
San FranciscoBiotechnology
Investors
Venrock Healthcare Capital PartnersRtw InvestmentsInvusFranklin TempletonEli Lilly And CompanyOrbi MedHbm Healthcare InvestmentsAdage Capital ManagementBalyasny Asset ManagementJanus Henderson Investors
Description
Lycia Therapeutics, based in South San Francisco, California, raised $75m in Series D funding. The round was co-led by Janus Henderson Investors and Balyasny Asset Management, with participation from various investors. The funds will be used to advance its lead cataLYTAC pipeline programs for food allergy and Graves’ disease. The company's leadership has recently strengthened its corporate governance.
Company Information
Company
Lycia Therapeutics, Inc.
Location
681 Gateway Blvd. 3rd Floor
San Francisco, California, United States
About
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
Fundz sees it the moment Lycia Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnology